Hanmi Science: Hanmi Pharm: Epiglenatide auto-injector wins MFDS approval
AI reading
★★★★ Bullish · Material event
Subsidiary product wins MFDS approval
An AI model read the opening section of the filing and rated it relative to the company's size. It can be wrong, so check the original filing on DART (Korean).
🤖 10/7 Why the stock moved
Hanmi Science rose on dual buying from foreign and institutional investors as renewed concerns over swine and avian flu outbreaks fueled a rally in pharma and diagnostics stocks.
Shares gained on rising epidemic alerts and strong institutional demand, with foreign and institutional investors net buying 14,441 and 4,697 shares, respectively, while a subsidiary's domestic drug approval added further momentum.
Other filings by Hanmi Science
- 10.07 ★★ Files report on major shareholding
- 09.29 ★★ Files report on major shareholding
- 09.23 ★★ Files report on major shareholding
- 09.01 ★★ Files report on major shareholding
- 08.26 ★★ Hanmi Pharm: Licenses out AML drug candidate HM43239
- 08.24 ★★★★★ Hanmi Pharmaceutical subsidiary signs HM17321 licensing deal
For information only. Not investment advice.